NASDAQ · Healthcare · Biotechnology
Rapport Therapeutics, Inc. Common Stock
RAPP
Rapport Therapeutics, Inc. CEO Abraham N. Ceesay · Market cap $1.1B.
$23.16
-0.43 · -1.82%
52w hi $52.9352w lo $22.06
Off 52w high 52.7%
81
STRONG
Current InsiderScore
Corp · 90d
11
11 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
10
3 strong · 7 notable
Analyst consensus
Strong Buy
Avg PT $65.56
Section 01
Recent Form 4 filings
15 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Oct 28 | James Healy | Buy | 3,772 | $21.00 | +$79K | 57 | |
| Oct 28 | James Healy | Buy | 6,933 | $21.00 | +$146K | 60 | |
| Oct 28 | James Healy | Buy | 6,395 | $21.00 | +$134K | 63 | |
| Oct 28 | James Healy | Buy | 952,380 | $21.00 | +$20.00M | 72 | |
| Oct 23 | Ramiro Sanchez | Buy | 3,600 | $27.35 | +$98K | 60 | |
| Oct 22 | John Maraganore | Buy | 1,172 | $26.92 | +$32K | 66 | |
| Oct 22 | Wendy B. Young | Buy | 3,789 | $26.39 | +$100K | 72 | |
| Oct 22 | John Maraganore | Buy | 8,239 | $26.38 | +$217K | 78 | |
| Oct 22 | Steven M Paul | Buy | 35,714 | $27.28 | +$974K | 81 | |
| Oct 22 | Paul M Silva | Buy | 3,680 | $27.07 | +$100K | 75 | |
| Oct 21 | Troy A. Ignelzi | Chief Financial Officer | Buy | 5,500 | $26.10 | +$144K | 69 |
| Sep 12 | Reid M Huber | Buy | 20,400 | $24.48 | +$499K | 59 | |
| Sep 12 | Steven M Paul | Buy | 28,284 | $24.50 | +$693K | 62 | |
| Sep 12 | Steven M Paul | Buy | 13,382 | $24.97 | +$334K | 56 | |
| Sep 11 | Wendy B. Young | Buy | 3,500 | $22.60 | +$79K | 46 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
DecJanFebMarAprMayJunJulAugSepOctNov